Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
20–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent.
Histologically confirmed relapsed or refractory CD20 positive FL grade 1-3a and 1 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or CD5, CD19, CD20 and CD23 positive relapse or refractory CLL.
Subjects must have adequate blood, liver, and kidney function.
Subjects who passed the provided periods from the last anti-cancer treatments at screening
ECOG Performance Status of 0-2
Life expectancy more than 24 weeks at screening
You may not be if
Current and past malignancy other than FL and CLL within 5 years prior to screening.
Known Richter's transformation
Previous autologous stem cell transplantation within 24 weeks prior to screening
Previous allogeneic stem cell transplantation
Known CNS involvement
History of significant cerebrovascular disease
Current cardiac disease requiring medical treatment
Chronic or ongoing active infectious disease requiring systemic treatment
Patients with pleural effusion or ascites detectable by physical examination
Positive serology test for any of HBsAg, anti-HBc or anti-HCV
Known HIV positive
Pregnant or lactating women
Women of childbearing potential and male patients not willing to use adequate contraception
Clareo Health | Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
